Research Analysts Issue Forecasts for LEXX Q4 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at Zacks Small Cap issued their Q4 2025 earnings per share estimates for Lexaria Bioscience in a research report issued on Tuesday, January 28th. Zacks Small Cap analyst J. Vandermosten anticipates that the company will post earnings of ($0.13) per share for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.42) per share. Zacks Small Cap also issued estimates for Lexaria Bioscience’s FY2027 earnings at ($0.38) EPS.

Lexaria Bioscience (NASDAQ:LEXX) last released its quarterly earnings data on Friday, January 10th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Lexaria Bioscience had a negative net margin of 1,473.04% and a negative return on equity of 88.88%.

Separately, HC Wainwright decreased their price target on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a report on Friday, January 24th.

Lexaria Bioscience Stock Up 0.6 %

NASDAQ LEXX opened at $1.82 on Wednesday. The business has a 50 day moving average price of $2.14 and a 200-day moving average price of $2.70. Lexaria Bioscience has a 52 week low of $1.43 and a 52 week high of $6.85. The company has a market cap of $31.94 million, a price-to-earnings ratio of -3.64 and a beta of 0.98.

Institutional Trading of Lexaria Bioscience

Several institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd raised its holdings in shares of Lexaria Bioscience by 47.8% in the 3rd quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after acquiring an additional 6,024 shares in the last quarter. Byrne Asset Management LLC grew its position in shares of Lexaria Bioscience by 132.1% in the 4th quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock worth $27,000 after buying an additional 7,400 shares during the last quarter. HighTower Advisors LLC bought a new stake in shares of Lexaria Bioscience in the 3rd quarter worth approximately $40,000. Renaissance Technologies LLC bought a new stake in shares of Lexaria Bioscience during the second quarter valued at approximately $63,000. Finally, Geode Capital Management LLC boosted its position in shares of Lexaria Bioscience by 31.0% during the third quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock valued at $459,000 after purchasing an additional 35,608 shares in the last quarter. Hedge funds and other institutional investors own 13.06% of the company’s stock.

Insider Activity

In related news, CEO Richard Christopher bought 22,828 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was acquired at an average price of $2.24 per share, for a total transaction of $51,134.72. Following the purchase, the chief executive officer now directly owns 22,828 shares in the company, valued at $51,134.72. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 26.40% of the company’s stock.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.